GlassScriptPhysician profile
John A Ellerton
NPI 1962585745
$9,042.70
in general payments reported to CMS, 2019-2025
58 companies · $252 in 2025
The $252 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,526 · 2020: $736 · 2021: $927 · 2022: $3,389 · 2023: $102 · 2024: $111 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $354 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $354.19 |
| Education | $110.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,395.99 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $639.04 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $526.45 | 2019-2025 | Libtayo |
| Pfizer INC. | $477.96 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $393.09 | 2019-2025 | Keytruda |
| Genentech USA, INC. | $383.07 | 2019-2022 | |
| Genzyme Corporation | $365.18 | 2019-2024 | |
| Seagen INC. | $365.09 | 2019-2022 | |
| Janssen Biotech, INC. | $351.19 | 2019-2022 | |
| Daiichi Sankyo INC. | $348.11 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $302.71 | 2019-2022 | |
| Celgene Corporation | $289.26 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $210.57 | 2019-2022 | |
| Eisai INC. | $194.36 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $193.98 | 2019-2022 |
Show all 56 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ellerton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.